Compare KB Financial Group, Inc. (KB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Sanofi SA — how do they compare? KB Financial Group, Inc. trades at $117.53 (market cap $41.21B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.5× KB Financial Group, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| KB | SNY | |
|---|---|---|
Market Cap | $41.21B | $104.30B |
Sector | Financials | Health |
52-Week High | $124.01 | $52.34 |
52-Week Low | $77.50 | $41.33 |
Dividend Yield | 2.67% | 5.55% |
Enterprise Value | — | $124.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial trades at $117.85, down 2.39% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.36, P/B of 0.98, and net income margin of 27.82%. Recent earnings beats in Q1 and Q2 2026 highlight operational strength, while cash flow trends show variability with a net inflow of $4.41T in 2025.
The outlook is positive given earnings momentum and undervaluation relative to peers, but risks include volatile cash flows and dependence on interest rates. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism for upside potential amid economic uncertainties.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
